323 related articles for article (PubMed ID: 12548585)
1. Bisphosphonates and metastatic breast carcinoma.
Lipton A
Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for zoledronic acid treatment of patients with bone metastases.
Berenson JR
Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
[TBL] [Abstract][Full Text] [Related]
5. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Rosen LS; Gordon DH; Dugan W; Major P; Eisenberg PD; Provencher L; Kaminski M; Simeone J; Seaman J; Chen BL; Coleman RE
Cancer; 2004 Jan; 100(1):36-43. PubMed ID: 14692022
[TBL] [Abstract][Full Text] [Related]
7. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
Maxwell C; Swift R; Goode M; Doane L; Rogers M
Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
Body JJ
Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
14. The role of bisphosphonates in breast cancer.
Coleman RE
Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer: bisphosphonate therapy for metastatic bone disease.
Body JJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
[TBL] [Abstract][Full Text] [Related]
17. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Saad F
Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate therapy for patients with breast carcinoma.
Plunkett TA; Rubens RD
Cancer; 2003 Feb; 97(3 Suppl):854-8. PubMed ID: 12548586
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
Smith MR
Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
